Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]			$ 1,071
Provision	[2]	$ 147	$ (5)	191	$ 12
Utilization and other	[3]			(349)
Balance, ending	[4]	913		913
Other Current Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning				816
Balance, ending		794		794
Other Noncurrent Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning				255
Balance, ending		119		119
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]			1,014
Provision				135
Utilization and other	[3]			(244)
Balance, ending	[4]	904		904
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]			0
Provision				28
Utilization and other	[3]			(28)
Balance, ending	[4]	0		0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]			57
Provision				29
Utilization and other	[3]			(78)
Balance, ending	[4]	$ 8		$ 8

[1] Included in Other current liabilities ($816 million) and Other noncurrent liabilities ($255 million).

[2] Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $50 million and $46 million for the three and six months ended July 3, 2022, respectively, and credits of $4 million and charges of $1 million for the three and six months ended July 4, 2021, respectively.

[3] Includes adjustments for foreign currency translation.

[4] Included in Other current liabilities ($794 million) and Other noncurrent liabilities ($119 million).